Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.

Chih-Cheng LaiChao-Hsien ChenCheng-Yi WangKuang-Hung ChenYa-Hui WangPo-Ren Hsueh

Published in: The Journal of antimicrobial chemotherapy (2021)

Remdesivir can help improve the clinical outcome of hospitalized patients with COVID-19 and a 5 day regimen, instead of a 10 day regimen, may be sufficient for treatment. Moreover, remdesivir appears as tolerable as other comparators or placebo.

Keyphrases

systematic review
randomized controlled trial
double blind
combination therapy
phase iii
placebo controlled
network analysis